NewMediX Information

NewMediX sources promising potential drugs and devices from universities, hospitals, contract research organizations, and biomedical and biotech companies. Scouting, screening, and selection of potential new drugs and devices will be done in close conjunction with investors, top scientists, pharmaceutical companies and patient organizations and will be based on the latest market developments. Besides using a very strict selection process, NewMediX is taking responsibility for accelerated transparent development and sustainable exit strategies for targeted medicines and devices within preferred therapeutic areas like (auto)immunology, oncology, anti-infectives, lifestyle diseases, cardiovascular- and degenerative diseases. NewMediX is launching massive funds financed by private and public parties. Each fund consists of a large number of very promising patents and/or licenses (Intellectual Property), thus reducing investment risks. These patents and/or licenses will be very efficiently developed on a project basis in a relatively short time frame, significantly reducing the average development time from clinical phase I - III. This approach will allow an investment horizon of 2-4 years.